Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adaptimmune/Genentech Deal Gives Powerful Push To Solid Tumor Cell Therapies

Executive Summary

Adaptimmune is getting a leg up in the race to develop iPSC-derived allogeneic cell therapies in a deal with the Roche subsidiary worth potentially more than $3bn.

You may also be interested in...



Roche Partnering Finds Upfront Fee Relief In Current Market

Barbara Lueckel, head of research technologies partnering, said Roche’s approach to platform deals has evolved with a focus on “generational technologies” to answer tough scientific questions. 

Big Pharma’s Busiest Deal-Makers In 2021 Were Less Prolific Than In 2020

Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.

Value Of BioPharma M&A Leaps in Q3

Merck & Co's proposed acquisition of Acceleron and a couple of big purchases from Sanofi drove up the value of the sector's M&A activities, according to the latest report from Biomedtracker

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145029

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel